BTG2017 FACULTY

BORJE ANDERSSON, MD, PHD

Picture
Professor OF MEDICINE AND PHARMACOLOGY At The University Of Texas MD Anderson Cancer Center

Dr. Borje Andersson, MD, PhD focuses his clinical research on research interest on 1) development of less toxic and more efficacious pre-transplant conditioning therapy, and 2) improving our understanding of leukemic cell resistance to bi-functional DNA-alkylating agents.  In reference to the first issue his group developed IV Busulfan, the first cytotoxic agent formulation ever to be approved by the FDA for use in pre-transplant conditioning therapy.  Further, his combination of once daily IV Busulfan and Fludarabine has rapidly become a new national standard for pre-transplant treatment for allogeneic stem cell transplantation for patients with myeloid malignancies.  His group is now evaluating the systematic use of pharmacokinetically (PK)-guided busulfan delivery to further optimize systemic drug exposure to further improve the treatment. He has identified a series of gene messages that are of importance for alkylating agent action, or lack thereof, in leukemic cells.